You are here:Home1/News Release2/U.S. FDA DESIGNATES FOR PRIORITY REVIEW EISAI’S SUPPLEMENTAL NEW DRUG APPLICATION FOR ANTIEPILEPTIC DRUG FYCOMPA? AS TREATMENT FOR PEDIATRIC PATIENTS WITH EPILEPSY
/wordpress/wp-content/uploads/2021/04/logo3.png00chen, chenyan/wordpress/wp-content/uploads/2021/04/logo3.pngchen, chenyan2018-05-31 00:00:002021-03-19 09:35:26U.S. FDA DESIGNATES FOR PRIORITY REVIEW EISAI’S SUPPLEMENTAL NEW DRUG APPLICATION FOR ANTIEPILEPTIC DRUG FYCOMPA? AS TREATMENT FOR PEDIATRIC PATIENTS WITH EPILEPSY